COMPASS Pathways plc
CMPS
NASDAQ
Healthcare
$13.62
+2.48%gain today
Market position
Market cap rank
#2404
of 2,614
1-day
+2.48%
1-month
+2.18%
6-month
+97.39%
YTD
+107.94%
1-year
+302.96%
5-year
-63.53%
Key figures
Market cap
$1.31B
P/E (live)
—
price ÷ annual EPS
P/E (reported)
-2.2
FY 2025
EPS
-$3.08
FY 2025
Dividend yield
0.00%
FY 2025
Dividend / share
$0.00
Gross margin
0.00%
FY 2025
Operating margin
0.00%
FY 2025
Net margin
0.00%
FY 2025
Return on equity
—
FY 2025
Valuation & financial health
Enterprise value
$516.5M
FY 2025
EV / EBITDA
-1.81
FY 2025
EV / Sales
0.00
FY 2025
Price / book
-12.21
FY 2025
Price / sales
0.00
FY 2025
Earnings yield
-44.62%
FY 2025
FCF yield
-24.37%
FY 2025
Debt / equity
-0.40
FY 2025
Current ratio
0.77
FY 2025
Return on assets
—
FY 2025
Return on invested capital
Financials · FY 2025
Revenue
$0
Gross profit
$0
Operating income
$-179.04M
EBITDA
$-285.6M
Net income
$-287.86M
Diluted EPS
-$3.08
Shares outstanding
93,504,836
Trading
Open
$13.36
Previous close
$13.29
Day range
$12.78 – $13.80
52-week range
$3.24 – $15.40
50-day avg
$11.34
200-day avg
$7.58
Volume
4,063,211
Avg volume
4,406,511
Beta
2.51
Price history
+302.96% over 1Y
Compare with peers
About COMPASS Pathways plc
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
Visit websiteCompany info
CEO
Kabir Kumar Nath
IPO date
Sep 18, 2020
Headquarters
London, GB
Country
Fundamentals are annual. Figures labeled with their fiscal year.
